FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311463033> ?p ?o ?g. }

• W4311463033 endingPage "2501" @default.
• W4311463033 startingPage "2489" @default.
• W4311463033 abstract "MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were included. Data collection and analyses were conducted from 2019 to 2021. Inclusion criteria were: diagnosis of MOG-antibody disease; AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis; brain and cord MRI at least 6 months from relapse; and Expanded Disability Status Scale (EDSS) score on the day of MRI. Brain white matter T2 lesions, T1-hypointense lesions, cortical and cord lesions were identified. Random forest models were constructed to classify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosis; a leave one out cross-validation procedure assessed the performance of the models. Based on the best discriminators between diseases, we proposed a guide to target investigations for MOG-antibody disease. One hundred and sixty-two patients with MOG-antibody disease [99 females, mean age: 41 (±14) years, median EDSS: 2 (0-7.5)], 162 with AQP4-neuromyelitis optica spectrum disorder [132 females, mean age: 51 (±14) years, median EDSS: 3.5 (0-8)], 189 with multiple sclerosis (132 females, mean age: 40 (±10) years, median EDSS: 2 (0-8)] and 152 healthy controls (91 females) were studied. In young patients (<34 years), with low disability (EDSS < 3), the absence of Dawson's fingers, temporal lobe lesions and longitudinally extensive lesions in the cervical cord pointed towards a diagnosis of MOG-antibody disease instead of the other two diseases (accuracy: 76%, sensitivity: 81%, specificity: 84%, P < 0.001). In these non-acute patients, the number of brain lesions < 6 predicted MOG-antibody disease versus multiple sclerosis (accuracy: 83%, sensitivity: 82%, specificity: 83%, P < 0.001). An EDSS < 3 and the absence of longitudinally extensive lesions in the cervical cord predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, sensitivity: 89%, specificity: 62%, P < 0.001). A workflow with sequential tests and supporting features is proposed to guide better identification of patients with MOG-antibody disease. Adult patients with non-acute MOG-antibody disease showed distinctive clinical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis. A careful inspection of the morphology of brain and cord lesions together with clinical information can guide further analyses towards the diagnosis of MOG-antibody disease in clinical practice." @default.
• W4311463033 created "2022-12-26" @default.
• W4311463033 creator A5001837884 @default.
• W4311463033 creator A5003010065 @default.
• W4311463033 creator A5004199452 @default.
• W4311463033 creator A5004637680 @default.
• W4311463033 creator A5008170559 @default.
• W4311463033 creator A5009536414 @default.
• W4311463033 creator A5010243880 @default.
• W4311463033 creator A5013583812 @default.
• W4311463033 creator A5016458414 @default.
• W4311463033 creator A5017658333 @default.
• W4311463033 creator A5018150387 @default.
• W4311463033 creator A5023332465 @default.
• W4311463033 creator A5024199819 @default.
• W4311463033 creator A5026026352 @default.
• W4311463033 creator A5029999073 @default.
• W4311463033 creator A5030381487 @default.
• W4311463033 creator A5031754069 @default.
• W4311463033 creator A5031911451 @default.
• W4311463033 creator A5033055839 @default.
• W4311463033 creator A5033264402 @default.
• W4311463033 creator A5038784094 @default.
• W4311463033 creator A5041570807 @default.
• W4311463033 creator A5044775116 @default.
• W4311463033 creator A5045865733 @default.
• W4311463033 creator A5047739488 @default.
• W4311463033 creator A5048043623 @default.
• W4311463033 creator A5051484919 @default.
• W4311463033 creator A5051943352 @default.
• W4311463033 creator A5056721367 @default.
• W4311463033 creator A5057395387 @default.
• W4311463033 creator A5059147261 @default.
• W4311463033 creator A5060777977 @default.
• W4311463033 creator A5063275381 @default.
• W4311463033 creator A5066879414 @default.
• W4311463033 creator A5068539014 @default.
• W4311463033 creator A5070021548 @default.
• W4311463033 creator A5076558532 @default.
• W4311463033 creator A5076585111 @default.
• W4311463033 creator A5077126971 @default.
• W4311463033 creator A5077301811 @default.
• W4311463033 creator A5082088239 @default.
• W4311463033 creator A5084674707 @default.
• W4311463033 creator A5088023477 @default.
• W4311463033 creator A5088512021 @default.
• W4311463033 creator A5089996126 @default.
• W4311463033 creator A5091582045 @default.
• W4311463033 creator A5091674171 @default.
• W4311463033 date "2022-12-14" @default.
• W4311463033 modified "2023-10-18" @default.
• W4311463033 title "Clinical and MRI measures to identify non-acute MOG-antibody disease in adults" @default.
• W4311463033 cites W1974581106 @default.
• W4311463033 cites W1975792132 @default.
• W4311463033 cites W2104362296 @default.
• W4311463033 cites W2129229339 @default.
• W4311463033 cites W2528474010 @default.
• W4311463033 cites W2542372902 @default.
• W4311463033 cites W2545267953 @default.
• W4311463033 cites W2598701066 @default.
• W4311463033 cites W2777074421 @default.
• W4311463033 cites W2786802845 @default.
• W4311463033 cites W2910017905 @default.
• W4311463033 cites W2910326450 @default.
• W4311463033 cites W2911065693 @default.
• W4311463033 cites W2912407698 @default.
• W4311463033 cites W2946864006 @default.
• W4311463033 cites W2948982345 @default.
• W4311463033 cites W2953920705 @default.
• W4311463033 cites W2979508089 @default.
• W4311463033 cites W2982158962 @default.
• W4311463033 cites W2990639672 @default.
• W4311463033 cites W2996580316 @default.
• W4311463033 cites W3082596735 @default.
• W4311463033 cites W3093436822 @default.
• W4311463033 cites W3126984125 @default.
• W4311463033 cites W3159467683 @default.
• W4311463033 cites W3161878813 @default.
• W4311463033 cites W3164559263 @default.
• W4311463033 cites W3171747481 @default.
• W4311463033 cites W3180022449 @default.
• W4311463033 cites W3195674796 @default.
• W4311463033 cites W4213354151 @default.
• W4311463033 cites W4226549435 @default.
• W4311463033 cites W4300817623 @default.
• W4311463033 doi "https://doi.org/10.1093/brain/awac480" @default.
• W4311463033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36515653" @default.
• W4311463033 hasPublicationYear "2022" @default.
• W4311463033 type Work @default.
• W4311463033 citedByCount "2" @default.
• W4311463033 countsByYear W43114630332023 @default.
• W4311463033 crossrefType "journal-article" @default.
• W4311463033 hasAuthorship W4311463033A5001837884 @default.
• W4311463033 hasAuthorship W4311463033A5003010065 @default.
• W4311463033 hasAuthorship W4311463033A5004199452 @default.
• W4311463033 hasAuthorship W4311463033A5004637680 @default.
• W4311463033 hasAuthorship W4311463033A5008170559 @default.
• W4311463033 hasAuthorship W4311463033A5009536414 @default.

• next